Amicus Therapeutics Announces Participation at World Muscle Society 2022

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 9/2/2026

1. PANW
2. GTLB
3. DELL
4. MDB
5. GOOGL

6. VRTS
7. SPY
8. HPE
9. USO
10. SNOW

Get Alerts FOLD Hot Sheet

Price: $14.49 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

PHILADELPHIA, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced four poster presentations highlighting its development program for Pompe disease will be included at the 27th International Hybrid Annual Congress of the World Muscle Society, being held October 11-15, 2022 both virtually and in Halifax, Canada.

Poster Presentations: Abstract Title: Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory patients with Pompe disease: an open-label phase I/II study (ATB200-02) (Poster #FP.17)

Presenter: Benedikt Schoser, MD, Department of Neurology, Ludwig-Maximilians-University of Munich, Munich, Germany
Flash Poster Presentation: Metabolic Myopathies – Wednesday, October 12, 4:05-4:10 p.m. ADT
- Location: Ballroom Salon
Poster Session: Metabolic Myopathies – Wednesday, October 12, 4:00-5:30 p.m. ADT
- Location: Ballroom B1-B2

Abstract Title: Living with Pompe disease in the UK: characterising the patient journey; burden on physical and emotional quality of life; and impact of COVID-19 (Poster #VP.32)

Presenter: Allan Muir, Chair of the Board of Trustees, Pompe Support Network, Petersfield, U.K.
Poster Session: Metabolic Myopathies – Wednesday, October 12, 4:00-5:30 p.m. ADT
Location: Virtual Platform

Abstract Title: Quantification of the burden, unmet needs, management, and COVID‑19 impact of living with Pompe disease in the UK: results of an online patient survey (Poster #VP.33)

Presenter: Val Buxton, Association for Glycogen Storage Disease (UK), Oldbury, U.K.
Poster Session: Metabolic Myopathies – Wednesday, October 12, 4:00-5:30 p.m. ADT
Location: Virtual Platform

Abstract Title: Indirect treatment comparison of three enzyme replacement treatments for late-onset Pompe disease: a network meta-analysis with patient-level and aggregate data (Poster #LSVP.19)

Presenter: Jeff Castelli, PhD, Amicus Therapeutics Inc., Philadelphia, PA, U.S.A.
Poster Session: Poster Session 4 – Friday, October 14, 5:00-6:00 p.m. ADT
Location: Virtual Platform

The posters will be made available on the Amicus website following their respective presentations at the congress.

For more information on the World Muscle Society 2022 Annual Congress, please visit www.wms2022.com.

About Amicus TherapeuticsAmicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow us on Twitter and LinkedIn.

CONTACTS:

Investors: Amicus Therapeutics Andrew FaughnanExecutive Director, Investor Relations[email protected](609) 662-3809

Media: Amicus Therapeutics Diana Moore Head of Global Corporate Communications[email protected](609) 662-5079

FOLD–G